Pre-emption Stifles One A Day Class Action, But Not In Play In Phillips' Colon Health-FTC Tilt
This article was originally published in The Tan Sheet
Executive Summary
A federal judge in California says FDA supplement labeling regs pre-empt challenges to structure/function claims in a class action suit against One-A-Day claims, but litigation in New Jersey against Phillips’ Colon Health claims is by the Federal Trade Commission, eliminating pre-emption from Bayer’s defense options.
You may also be interested in...
Expand Federal Pre-emption In Supplement Claims Complaints? Not So Fast, Says Ninth Circuit
The ruling reverses district court’s dismissal of class action against CVS after determining the lower court erred in determining federal law pre-empted the consumer plaintiff’s state-law causes of action. It says while consumers are prohibited under California law from arguing that a product doesn’t provide a benefit that isn’t claimed, plaintiffs can demand substantiation for claims that are made.
Industry Looking For Details As Legislation Looks Likely On Hemp Ingredients' Use In Supplements
Whether lawmakers will favor legislation aligning with FDA’s thinking or hemp industry’s preferences isn’t known, says Jonathan Miller, US Hemp Roundtable general counsel. “We're feeling pretty confident that something's going to happen.”
US Hemp Industry Group Rings Alarm With Congress About FDA’s Safety Conclusions
US Hemp Roundtable general counsel cautions congressional leaders about “agency’s misguided use of incomplete safety data as the basis for its continued refusal to regulate CBD as a dietary supplement or food additive.”